The aim of this trial was to explore the efficacy and safety of CD8 + CD56+ NKT cell immunotherapy combined with gefitinib in patients with advanced EGFR-mutated NSCLC. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.